HEPHAISTOS-Pharma is a preclinical biotechnology company focused on developing innovative immunotherapies for cancer treatment, particularly targeting the innate immune response. Their lead product, ONCO-Boost, is a first-in-class TLR4 agonist designed to enhance the immune system's ability to recognize and attack "cold" tumors, which are typically resistant to existing therapies. By stimulating monocytes and dendritic cells, ONCO-Boost aims to recruit and activate various immune defenses, including CD4 and CD8 T cells, thereby transforming these tumors into "hot" targets for immune attack. This approach not only seeks to improve the efficacy of current immunotherapies but also aims to address the significant unmet medical needs in treating hard-to-access cancers, such as osteosarcoma.

The company is advancing its ONCO-Boost platform through substantial funding, including a recent €10.3 million investment to support its clinical development. HEPHAISTOS-Pharma has garnered recognition and support from various prestigious programs, including the EIC Accelerator and the French National Research Agency, which will help fund clinical trials. Their innovative strategy positions them as a key player in the oncology field, with the potential to significantly enhance treatment outcomes for patients with difficult-to-treat cancers.

France

HEPHAISTOS-Pharma is a biotechnology company developing next generation immunotherapies against cancer. The company was co-founded in 2018 and has raised significant seed funding for its innovative work in cancer treatment.

HEPHAISTOS-Pharma

Company Details